Sugi Predict

Sugi Predict / Compounds / SCHEMBL147200

SCHEMBL147200

SCHEMBL147200

NC(=S)Nc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.59
▸ ALDH1A1 P00352 5/20 0.58
▸ RAB9A P51151 2/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ NPC1 O15118 1/20 0.57
▸ KDM4E B2RXH2 2/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ ALOX12 P18054 1/20 0.53
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ HPGD P15428 2/20 0.51
▸ LMNA P02545 1/20 0.51
▸ TP53 P04637 1/20 0.50
▸ TYR P14679 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ TAS2R38 P59533 1/20 0.50
▸ HSD17B10 Q99714 1/20 0.50
▸ GAA P10253 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639347 1.00 L3MBTL1 (0.59) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL9311245 0.84 L3MBTL1 (0.52) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL7593748 0.84 L3MBTL1 (0.71) L3MBTL1ALDH1A1SMN1; SMN2KDM4EALOX12
SCHEMBL5464387 0.83 L3MBTL1 (0.50) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL29838495 0.83 L3MBTL1 (0.50) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL29838503 0.82 ALDH1A1 (0.70) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL5449341 0.82 ALDH1A1 (0.70) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL11162760 0.81 L3MBTL1 (0.49) L3MBTL1ALDH1A1RAB9ASMN1; SMN2NPC1
SCHEMBL31389917 0.80 L3MBTL1 (0.56) L3MBTL1ALDH1A1RAB9ASMN1; SMN2KDM4E
SCHEMBL790145 0.80 L3MBTL1 (0.47) L3MBTL1ALDH1A1SMN1; SMN2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114432901-B Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2023-04-11 — — CN claimed
CN-114432901-A Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2022-05-06 — — CN claimed
CN-112582673-A Lithium ion battery electrolyte and lithium ion battery 比亚迪股份有限公司 2021-03-30 — — CN claimed
CN-102070556-B 5-benzyl-4-alkyl-2-aminothiazole as well as preparation and application of 5-benzyl-4-alkyl-2-aminothiazole UNIV HUNAN 2013-03-20 — — CN claimed
CN-101687816-A Triaminopyrimidine derivatives as the CDC25 inhibitors of phosphatases IPSEN PHARMA SAS 2010-03-31 — — CN claimed
CN-115636815-B Preparation method and application of pomalidomide connected urea compound 新乡学院 2023-10-27 — — CN disclosed
US-20230286933-A1 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SOUTHERN RES INST (US) 2023-09-14 — — US disclosed
US-20230286933-A1 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SOUTHERN RES INST (US) 2023-09-14 — — US disclosed
CN-114249702-B N-aryl- [2,4 '-dithiazole ] -2' -amine compound and preparation and application thereof 沈阳药科大学 2023-09-05 — — CN disclosed
US-20230263167-A1 METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-08-24 — — US disclosed
US-11718593-B2 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases SOUTHERN RESEARCH INSTITUTE (US) 2023-08-08 — — US disclosed
US-11718593-B2 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases SOUTHERN RESEARCH INSTITUTE (US) 2023-08-08 — — US disclosed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 — — WO disclosed
WO-2000047194-A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 — — WO disclosed
US-5998399-A Guanidine derivatives useful in therapy as inhibitors of nitric oxide synthetase ASTRA AKTIEBOLAG (SE) 1999-12-07 — — US disclosed
WO-1999040088-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1999-08-12 — — WO disclosed
EP-0690851-B1 GUANIDINE DERIVATIVES USEFUL IN THERAPY ASTRA AB (SE) 1999-05-19 — — EP disclosed
US-5885985-A Guanidine derivatives useful in therapy ASTRA AKTIEBOLAG (SE) 1999-03-23 — — US disclosed
EP-0690851-A1 GUANIDINE DERIVATIVES USEFUL IN THERAPY Astra Aktiebolag (SE) 1996-01-10 — — EP disclosed
WO-1994021621-A1 GUANIDINE DERIVATIVES USEFUL IN THERAPY ASTRA AKTIEBOLAG (SE) 1994-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718593-B2 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases SMN1; SMN2, TDP2, TDP1 L3MBTL1 249/4885ALDH1A1 1090/4885RAB9A 2604/4885
US-20230286933-A1 2,5-ARYL-THIAZOLE ANALOGS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SMN1; SMN2, TDP2, TDP1 L3MBTL1 249/4885ALDH1A1 1090/4885RAB9A 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.